

**Abemaciclib**

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

**Abiraterone**

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

**Adalimumab**

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Rheumatoid arthritis Crohn disease site

**Afatinib**

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

**All-trans retinoic acid**

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

**Allopurinol**

Section	Indications
Supportive medicines Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

## Anastrozole

### Section

Hormones and antihormones

Oral > Solid: 1 mg tablet

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Arsenic trioxide

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

### Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

## Asparaginase

### Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

## Atezolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

## Axicabtagene ciloleucel

### Section

Antineoplastics and supportive medicines

Cell suspension for infusion:  $2 \times 10^6$  anti-CD19 CAR-positive viable T-cells per kg of body weight.

### Indications

Diffuse large B-cell lymphomas

## Azacitidine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

### Indications

Myeloid leukaemia

## Azathioprine

### Section

Immunomodulators for non-malignant disease

Oral > Solid: 50 mg

Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 50 mg (scored); 25 mg

### Indications

Relapsing-remitting multiple sclerosis

Failure or rejection of transplanted organs or tissues

## Bendamustine

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

## Bicalutamide

### Section

Hormones and antihormones

Oral > Solid: 50 mg

### Indications

Malignant neoplasms of prostate

## Binimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

## Bleomycin

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

## Bortezomib

### Section

#### Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

### Indications

Plasma cell myeloma

## Calcium folinate (leucovorin calcium)

### Section

#### Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of rectum

Malignant neoplasms of colon

Osteosarcoma of bone and articular cartilage of unspecified sites

## Capecitabine

### Section

#### Cytotoxic medicines

Oral > Solid: 150 mg tablet; 500 mg tablet

### Indications

Malignant neoplasms of colon

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

## Carboplatin

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### Indications

Other specified gliomas of brain

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

## Cemiplimab

### Section

Immunomodulators

### Indications

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

## Certolizumab pegol

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

## Chlorambucil

### Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ciclosporin

### Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

### Indications

Failure or rejection of transplanted organs or tissues

## Cisplatin

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant neoplasms of nasopharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

## Cladribine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

### Indications

Langerhans cell histiocytosis

## Cobimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

## Crizotinib

### Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

## Cyclophosphamide

### Section

Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid: 25 mg; 50 mg

Oral > Solid: 25 mg; 50 mg tablet

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Plasma cell myeloma

Other specified malignant neoplasms of breast

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of breast

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

## Cytarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Langerhans cell histiocytosis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Dabrafenib

### Section

#### Targeted therapies

Oral > Solid: 50 mg; 75 mg

### Indications

Other specified melanoma of skin

## Dacarbazine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

### Indications

Hodgkin lymphoma

## Dactinomycin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

### Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

## Daratumumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

### Indications

Plasma cell myeloma



## Dasatinib

### Section

#### Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Daunorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

## Dexamethasone

### Section

#### Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

### Indications

Plasma cell myeloma

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Docetaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

### Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

## Doxorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Diffuse large B-cell lymphomas

Plasma cell myeloma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Doxorubicin (as pegylated liposomal)

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Kaposi sarcoma of unspecified primary site

## Durvalumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

### Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of bronchus or lung

## Encorafenib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

## Enzalutamide

### Section

Hormones and antihormones

Oral > Solid: 40 mg

### Indications

Therapeutic equivalent to abiraterone for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

## Erlotinib

### Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

## Etanercept

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

## Etoposide

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Everolimus

### Section

#### Targeted therapies

Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)

### Indications

Other specified gliomas of brain

## Filgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

Acquired neutropaenia

## Fingolimod

### Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

### Indications

Relapsing-remitting multiple sclerosis

## Fludarabine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Fluorouracil

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Parenteral > General injections > IV: 50 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of breast

Malignant neoplasms of colon

## Flutamide

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

## Fulvestrant

### Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

### Indications

Malignant neoplasms of breast

## Gefitinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

## Gemcitabine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

## Golimumab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

## Goserelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of prostate

## Hydrocortisone

### Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

### Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

## Hydroxycarbamide (hydroxyurea)

### Section

#### Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

### Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

## Ibrutinib

### Section

#### Targeted therapies

Oral > Solid: 140 mg

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ifosfamide

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Imatinib

### Section

#### Targeted therapies

Oral > Solid: 100 mg; 400 mg

### Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

## Infliximab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to **adalimumab** for

Axial spondyloarthritis

Therapeutic equivalent to **adalimumab** for

Rheumatoid arthritis

Therapeutic equivalent to **adalimumab** for

Crohn disease site

## Irinotecan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

## Lenalidomide

### Section

Immunomodulators

Oral > Solid: 25 mg

### Indications

Plasma cell myeloma

## Leuprorelin

### Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

### Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

## Lisocabtagene maraleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to **axicabtagene ciloleucel** for

Diffuse large B-cell lymphomas



## Melphalan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

### Indications

Plasma cell myeloma

## Mercaptopurine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

## Mesna

### Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

### Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

## Methotrexate

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

#### Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of breast

Lymphoid leukaemia, not elsewhere classified

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Langerhans cell histiocytosis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Crohn disease site

Psoriatic arthritis

## Methylprednisolone

### Section

#### Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

### Indications

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

## Nilotinib

### Section

#### Targeted therapies

Oral > Solid: 150 mg capsule; 200 mg capsule

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Nilutamide

### Section

#### Hormones and antihormones

### Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

## Nivolumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

## Osimertinib

### Section

#### Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

### Indications

Other specified malignant neoplasms of bronchus or lung

## Oxaliplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

## Paclitaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

### Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

## Palbociclib

### Section

#### Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

### Indications

Other specified malignant neoplasms of breast

## Pegaspargase

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

## Pegfilgrastim

### Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pembrolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

### Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

## Pertuzumab

### Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

### Indications

Carcinoma of breast, specialised type

## Prednisolone

### Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Lymphoid leukaemia, not elsewhere classified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of prostate

Langerhans cell histiocytosis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Prednisone

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphomas

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

## Procarbazine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

## Rasburicase

### Section

Supportive medicines

Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution

### Indications

Tumour lysis syndrome

## Realgar-indigo naturalis formulation

### Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

### Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

## Ribociclib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

## Rituximab

### Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

### Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

## Tacrolimus

### Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

### Indications

Failure or rejection of transplanted organs or tissues

## Tamoxifen

### Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Thalidomide

### Section

Immunomodulators  
Oral > Solid: 50 mg

### Indications

Plasma cell myeloma

## Tioguanine

### Section

Cytotoxic medicines  
Oral > Solid: 40 mg

### Indications

Lymphoid leukaemia, not elsewhere classified

## Tisagenlecleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Tislelizumab

### Section

Immunomodulators  
Parenteral > General injections > IV: 100 mg per 10 mL

### Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

## Toripalimab

### Section

Immunomodulators  
Parenteral > General injections > IV: 240 mg per 6 mL in vial

### Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus

## Trametinib

### Section

Targeted therapies  
Oral > Solid: 0.5 mg; 2 mg

### Indications

Other specified melanoma of skin



## Trastuzumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Trastuzumab emtansine

### Section

#### Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Triptorelin

### Section

#### Hormones and antihormones

### Indications

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of prostate

## Vemurafenib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

## Vinblastine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Langerhans cell histiocytosis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

## Vincristine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Retinoblastoma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

## Vinorelbine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Oral > Solid: 20 mg; 30 mg; 80 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Rhabdomyosarcoma primary site

## Zanubrutinib

### Section

#### Targeted therapies

Oral > Solid: 80 mg

### Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Zoledronic acid

### Section

#### Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

### Indications

Malignant neoplasm metastasis in bone or bone marrow